“We are already using a lot of dexmedetomidine in ICUs. This study adds to our comfort level that dexmedetomidine is cost-effective,” said Marcia Buck, a clinical pharmacy coordinator at the University of Virginia Children’s Hospital. “With the downsides of using propofol in terms of its toxicity profile, it is good to have this kind of data available.”